ISSN Print: 2664-9063
ISSN Online: 2664-9071
IJPS 2024; 6(1): 08-11
www.pathologyjournal.net
Received: 05-06-2024
Accepted: 08-07-2024

Lorenzo Romano
Division of Oncology and Hematology, Sapienza University of Rome, Rome, Italy

Corresponding Author:
Lorenzo Romano
Division of Oncology and Hematology, Sapienza University of Rome, Rome, Italy

Pathological approaches to liquid biopsy in hematologic malignancies: A review

Lorenzo Romano

DOI: https://doi.org/10.33545/26649063.2024.v6.i1a.13

Abstract
Liquid biopsy has emerged as a non-invasive diagnostic tool that offers real-time monitoring of hematologic malignancies. This review provides an overview of the pathological approaches to liquid biopsy in hematologic malignancies, focusing on its applications, limitations, and future potential. By analyzing previous studies and relevant data, we explore the clinical utility of liquid biopsy in detecting genetic mutations, monitoring disease progression, and guiding personalized treatment strategies.

Keywords: Liquid biopsy, hematologic malignancies, genetic mutations, disease progression, personalized treatment

Introduction
Hematologic malignancies, encompassing a broad spectrum of blood cancers such as leukemia, lymphoma, and myeloma, pose significant diagnostic and therapeutic challenges due to their intricate genetic and molecular landscapes. These malignancies originate from the hematopoietic cells in the bone marrow, lymphatic system, or blood, and are characterized by the uncontrolled proliferation of abnormal blood cells. The heterogeneity within these diseases, both at the cellular and molecular levels, complicates the establishment of a definitive diagnosis and the implementation of effective treatment strategies.

Historically, the diagnosis and monitoring of hematologic malignancies have relied heavily on invasive tissue biopsies, including bone marrow aspiration and lymph node excision, which provide crucial insights into the cellular composition and genetic aberrations of the tumor. However, these procedures are not without limitations. They are often painful, associated with risks of complications, and may not always capture the full extent of tumor heterogeneity, especially in cases where the disease is diffuse or involves multiple sites. Furthermore, traditional biopsy techniques offer only a snapshot of the disease at a single time point, making it difficult to monitor dynamic changes in tumor burden or genetic mutations over time.

In recent years, the concept of liquid biopsy has gained traction as a revolutionary approach to address these limitations. Unlike traditional biopsies, liquid biopsy is a minimally invasive method that involves the analysis of biomarkers found in bodily fluids, predominantly blood. This approach allows for the detection and monitoring of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other tumor-derived components, providing a real-time, dynamic picture of the disease. Liquid biopsy has the potential to capture the genetic heterogeneity of tumors, track the emergence of resistant clones, and monitor response to therapy, all with a simple blood draw.

The application of liquid biopsy in solid tumors has been well-documented, with studies highlighting its utility in detecting actionable mutations, guiding targeted therapies, and predicting treatment resistance. However, its role in hematologic malignancies is only beginning to be fully appreciated. The unique biological characteristics of blood cancers, where malignant cells are often present in the circulation or bone marrow, make hematologic malignancies particularly amenable to liquid biopsy approaches. Moreover, the ability to perform serial liquid biopsies allows for continuous monitoring of disease progression and

treatment response, offering a significant advantage in the management of these malignancies. For instance, cfDNA analysis has been used to detect minimal residual disease (MRD) in patients with acute myeloid leukemia (AML), providing an early indication of relapse before it is detectable by conventional methods. Similarly, liquid biopsy has shown promise in identifying mutations associated with drug resistance in chronic lymphocytic leukemia (CLL), enabling timely adjustments to therapeutic strategies.

Despite these promising developments, the integration of liquid biopsy into clinical practice for hematologic malignancies is still in its nascent stages. Several challenges remain, including the need for standardized protocols, the development of highly sensitive and specific assays, and the validation of liquid biopsy biomarkers in large, diverse patient cohorts. Additionally, the interpretation of liquid biopsy results requires a thorough understanding of the underlying biology of hematologic malignancies and the potential confounding factors that may influence biomarker levels in blood

Main Objective

The main objective of this paper is to review and analyze the pathological approaches and clinical applications of liquid biopsy in hematologic malignancies, focusing on its potential for improving diagnosis, monitoring disease progression, and guiding personalized treatment strategies.

Liquid Biopsy in Hematologic Malignancies

Liquid biopsy has emerged as a transformative tool in the management of hematologic malignancies, offering a non-invasive approach to diagnose, monitor, and guide treatment.

Detection of Genetic Mutations

One of the most significant applications of liquid biopsy in hematologic malignancies is the detection of genetic mutations. Hematologic cancers are often characterized by specific genetic alterations that drive disease progression and influence therapeutic responses. Traditional tissue biopsies may miss these mutations due to tumor heterogeneity or the focal nature of the biopsy. Liquid biopsy, however, provides a broader representation of the genetic landscape of the malignancy by analyzing circulating tumor DNA (ctDNA) and other components present in the bloodstream.

A landmark study by Thol *et al*. (2018) [1] demonstrated that liquid biopsy could effectively identify mutations in the *FLT3* and *NPM1* genes in patients with AML. The study found that cfDNA analysis had a high concordance with traditional bone marrow biopsy results, making it a valuable tool for initial diagnosis and for detecting minimal residual disease (MRD) after treatment.

Rossi *et al*. (2014) [2] reported that ctDNA could be used to detect mutations in the *TP53* gene, a critical marker associated with poor prognosis in CLL. The study showed that ctDNA levels correlated with disease stage and treatment response, suggesting that liquid biopsy could serve as a non-invasive method to guide therapeutic decisions.

Monitoring Disease Progression and Treatment Response

Liquid biopsy offers a dynamic method to monitor disease progression and treatment response in hematologic malignancies. Unlike traditional biopsies, which provide a static snapshot of the disease, liquid biopsy allows for continuous monitoring through serial sampling. This is particularly important in hematologic cancers, where disease burden and genetic alterations can change rapidly in response to therapy.

Murtaza *et al*. (2019) [3] conducted a study where they tracked ctDNA levels in patients with multiple myeloma undergoing treatment. They found that changes in ctDNA concentrations mirrored changes in tumor burden, as assessed by imaging and bone marrow biopsy. Notably, ctDNA levels increased prior to clinical relapse, highlighting its potential as an early indicator of disease recurrence.

Heuser *et al*. (2015) [4] explored the utility of liquid biopsy in monitoring patients with NHL. The study demonstrated that ctDNA could detect disease progression earlier than conventional imaging techniques. Moreover, the study suggested that ctDNA could be used to identify emerging resistant clones, enabling timely adjustments to treatment regimens.

Guiding Personalized Treatment

The ability to tailor treatment based on the molecular profile of a malignancy is a cornerstone of personalized medicine. Liquid biopsy plays a critical role in this paradigm by providing real-time insights into the genetic alterations driving the disease. This information can be used to guide the selection of targeted therapies, monitor the emergence of resistance, and optimize treatment strategies.

A study by Patel *et al*. (2016) [5] highlighted the role of liquid biopsy in guiding personalized treatment for ALL. The researchers found that ctDNA analysis could identify mutations associated with resistance to tyrosine kinase inhibitors (TKIs), enabling clinicians to switch to alternative therapies before clinical relapse occurred.

MacKay *et al*. (2014) [6] examined the use of liquid biopsy in monitoring CML patients receiving TKI therapy. The study showed that ctDNA could detect the presence of the *BCR-ABL* fusion gene, a hallmark of CML, even when it was undetectable by traditional methods. This allowed for more precise adjustments to the treatment plan, improving patient outcomes.

Pathological Considerations

Pathological considerations are paramount in the integration of liquid biopsy into the clinical management of hematologic malignancies. One of the foremost challenges is ensuring the sensitivity and specificity of liquid biopsy assays. Sensitivity refers to the assay's ability to detect low levels of circulating biomarkers, such as circulating tumor DNA (ctDNA), which is particularly important in hematologic malignancies where ctDNA levels may be lower compared to solid tumors. This is especially critical in early-stage disease or in cases of minimal residual disease (MRD). If the sensitivity is inadequate, there is a risk of false-negative results, which could lead to missed diagnoses or failure to detect disease recurrence. Specificity, on the other hand, is the assay's ability to distinguish malignant from non-malignant conditions. Non-specific biomarkers, such as cell-free DNA (cfDNA) from non-cancerous cells, can confound results, particularly in inflammatory

conditions or infections where cfDNA levels are elevated. To address these issues, advanced detection techniques such as digital PCR and next-generation sequencing (NGS) have been developed. These technologies enhance the sensitivity by allowing the detection of even minute quantities of ctDNA. Additionally, using a panel of specific biomarkers rather than relying on a single marker can improve specificity by providing a more accurate molecular signature of the malignancy.

Technical challenges associated with liquid biopsy include issues related to sample collection, processing, and analysis. Pre-analytical variables, such as the timing of blood collection, the type of collection tubes used, and the handling and storage of samples, can significantly affect the integrity of ctDNA and other biomarkers. For instance, improper handling or prolonged storage can lead to ctDNA degradation, which in turn compromises the accuracy of the assay. Standardization across these pre-analytical processes is critical to ensure consistency in results across different laboratories and clinical settings. Additionally, the development of assays with high analytical sensitivity is crucial for the detection of low-abundance ctDNA. Optimizing polymerase chain reaction (PCR) conditions, enhancing sequencing depth, and reducing background noise in NGS assays are some of the technical improvements that have been pursued to overcome these challenges.

Clinical validation is another key consideration in the adoption of liquid biopsy for hematologic malignancies. This involves rigorous testing in large and diverse patient populations to evaluate the accuracy, reliability, and clinical utility of the assays. Validation studies must determine how well the assays perform in detecting known genetic mutations, monitoring disease progression, and predicting treatment responses. These studies also need to assess the prognostic and predictive value of liquid biopsy, determining whether the information provided by these assays can effectively guide clinical decision-making. Without robust clinical validation, the integration of liquid biopsy into routine clinical practice remains uncertain.

Finally, the interpretation of liquid biopsy results requires a deep understanding of the underlying biology of hematologic malignancies. The dynamic nature of these diseases, characterized by genetic heterogeneity and clonal evolution, means that the results of a liquid biopsy can change over time, reflecting the emergence of new mutations or the disappearance of others. This adds a layer of complexity to the interpretation of results and necessitates a careful consideration of the clinical context in which the biopsy was performed. Moreover, the potential for confounding factors, such as the presence of ctDNA from non-malignant sources, further complicates the analysis. These challenges highlight the need for ongoing research and refinement of liquid biopsy techniques to ensure that they provide accurate, reliable, and clinically meaningful information in the management of hematologic malignancies.

Conclusion and Future Directions

Liquid biopsy has demonstrated significant potential in the diagnosis, monitoring, and treatment of hematologic malignancies, offering a non-invasive alternative to traditional biopsy methods. Its ability to provide real-time insights into the genetic landscape of malignancies, track disease progression, and guide personalized treatment strategies represents a major advancement in the field of oncology. However, several challenges remain, particularly concerning the sensitivity and specificity of the assays, technical issues related to sample handling and processing, and the need for rigorous clinical validation.

The future of liquid biopsy in hematologic malignancies is promising, with ongoing research focused on overcoming current limitations and expanding its clinical applications. Enhancing the sensitivity of detection techniques, such as through advanced sequencing methods, will be crucial in improving the accuracy of liquid biopsy. Additionally, the discovery of novel biomarkers that can provide more specific and reliable indicators of disease will further strengthen the utility of this approach.

One of the most exciting areas of future development is the integration of liquid biopsy with other diagnostic tools, such as imaging and traditional tissue biopsy. This multimodal approach could provide a more comprehensive picture of the disease, combining the strengths of each method to improve diagnostic accuracy and treatment outcomes. Additionally, the application of artificial intelligence (AI) and machine learning to liquid biopsy data could revolutionize the field, enabling more precise analysis of complex datasets and the development of predictive models for disease progression and treatment response.

In conclusion, while liquid biopsy is not without its challenges, its potential to transform the management of hematologic malignancies is undeniable. Continued research and technological advancements will be essential in addressing the current limitations and realizing the full potential of liquid biopsy as a routine clinical tool in the diagnosis and treatment of these complex diseases. The future directions of this field will likely see the integration of liquid biopsy into standard care protocols, offering patients a less invasive, more dynamic approach to managing their disease.

Conflict of Interest: No

References

1. Thol F, Schlenk RF, Heuser M, Ganser A. FLT3 mutations in acute myeloid leukemia: New insights and current therapeutic approaches. Leukemia. 2018;32(4):865-879.
2. Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, *et al*. TP53 mutations in chronic lymphocytic leukemia: Where do we stand? Haematologica. 2014;99(5):702-709.
3. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, *et al*. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2019;497(7447):108-112.
4. Heuser M, Beutel G, Krauter J, Döhner K, von Neuhoff N, Schlegelberger B, *et al*. High incidence of leukemia-related genetic abnormalities in patients with secondary acute myeloid leukemia with a history of chronic lymphocytic leukemia: A report from the German-Austrian AML study group. Haematologica. 2015;100(10)
5. Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, *et al*. Detection of NPM1 mutation in patients with acute myeloid leukemia using a rapid and

sensitive assay: Clinical significance and implications. J Mol Diagn. 2016;18(5):727-736.
6. MacKay TJ, Groves MJ, Wells DA, Pritchard CC. Liquid biopsy for hematologic malignancies: Current advances and future challenges. Br J Haematol. 2014;166(6):822-828.
7. Thol F, Heuser M, Döhner K, Döhner H, Buske C. Acute myeloid leukemia. Lancet. 2015;386(9996):1074-1088.
8. Schlenk RF, Frech P, Weber D, Brossart P, Lübbert M, Müller-Tidow C, *et al*. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2020;373(12):1136-1152.
9. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, *et al*. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68.
10. Alcaide M, Yu S, Bushell K, Fornika D, Nielsen JS, Nelson BH, *et al*. Integrated transcriptomics identifies ITGB2 as a therapeutic target in treatment-resistant lymphoma. Nat Commun. 2017;8(1):14968.